JP2023536631A5 - - Google Patents
Info
- Publication number
- JP2023536631A5 JP2023536631A5 JP2023507634A JP2023507634A JP2023536631A5 JP 2023536631 A5 JP2023536631 A5 JP 2023536631A5 JP 2023507634 A JP2023507634 A JP 2023507634A JP 2023507634 A JP2023507634 A JP 2023507634A JP 2023536631 A5 JP2023536631 A5 JP 2023536631A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061112P | 2020-08-04 | 2020-08-04 | |
| US63/061,112 | 2020-08-04 | ||
| PCT/US2021/044356 WO2022031710A2 (en) | 2020-08-04 | 2021-08-03 | Multispecific binding agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536631A JP2023536631A (ja) | 2023-08-28 |
| JP2023536631A5 true JP2023536631A5 (https=) | 2024-08-08 |
| JP7840312B2 JP7840312B2 (ja) | 2026-04-03 |
Family
ID=80120131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507634A Active JP7840312B2 (ja) | 2020-08-04 | 2021-08-03 | 多重特異性結合性作用剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240010751A1 (https=) |
| EP (1) | EP4192878A4 (https=) |
| JP (1) | JP7840312B2 (https=) |
| CN (1) | CN116390939A (https=) |
| AU (1) | AU2021322114A1 (https=) |
| CA (1) | CA3188068A1 (https=) |
| WO (1) | WO2022031710A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3251615A1 (en) * | 2022-01-31 | 2023-08-03 | Centessa Pharmaceuticals (Uk) Limited | Activable Bispecific Anti-CD47 and Anti-PD-L1 Proteins and Their Uses |
| WO2023245022A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target b7h3 and gd2 and uses thereof |
| AU2023383441A1 (en) * | 2022-11-18 | 2025-06-05 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| WO2024148276A1 (en) | 2023-01-06 | 2024-07-11 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3255060A1 (en) * | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CA3080120C (en) * | 2017-10-27 | 2023-11-21 | New York University | Anti-galectin-9 antibodies and uses thereof |
| BR112020010020A2 (pt) | 2017-11-20 | 2020-11-10 | Taizhou Mabtech Pharmaceutical Co., Ltd | uma proteína de fusão bifuncional direcionada a cd47 e pd-l1 |
| EP3722322A4 (en) * | 2017-12-04 | 2021-09-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | ANTI-PD-L1 / ANTI-CD47 BISPECIFIC ANTIBODY HAVING A NATURAL ANTIBODY STRUCTURE AND IN THE FORM OF A HETERODIMER, AND ASSOCIATED PREPARATION |
| WO2019179434A1 (en) * | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/cd47 antibody molecules |
| WO2022031680A1 (en) * | 2020-08-04 | 2022-02-10 | Exelixis, Inc. | Cd47 binding agents and uses thereof |
| US20230303699A1 (en) * | 2020-08-04 | 2023-09-28 | Exelixis, Inc. | Pd-l1 binding agents and uses thereof |
-
2021
- 2021-08-03 CN CN202180067259.6A patent/CN116390939A/zh active Pending
- 2021-08-03 AU AU2021322114A patent/AU2021322114A1/en active Pending
- 2021-08-03 EP EP21852525.1A patent/EP4192878A4/en active Pending
- 2021-08-03 WO PCT/US2021/044356 patent/WO2022031710A2/en not_active Ceased
- 2021-08-03 CA CA3188068A patent/CA3188068A1/en active Pending
- 2021-08-03 JP JP2023507634A patent/JP7840312B2/ja active Active
- 2021-08-03 US US18/018,864 patent/US20240010751A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7375122B2 (ja) | ヒト化、マウスまたはキメラ抗ｃｄ４７モノクローナル抗体 | |
| US10781256B2 (en) | Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP2023536631A5 (https=) | ||
| JP2024150445A5 (https=) | ||
| JP2021533726A5 (https=) | ||
| JP2021503455A5 (https=) | ||
| JP2025506143A5 (https=) | ||
| JP2013502913A5 (https=) | ||
| JP2018512175A5 (https=) | ||
| JP2023089245A5 (https=) | ||
| AU2022273136A1 (en) | Binding molecule against dll3 and use thereof | |
| JP2024001073A5 (https=) | ||
| JP2020528936A5 (https=) | ||
| JP2025510642A5 (https=) | ||
| JP2024509501A5 (https=) | ||
| TW202204424A (zh) | 用於人類疾病之治療的ｃｄ３８抗體 | |
| JP2023533533A5 (https=) | ||
| JP2023536630A5 (https=) | ||
| WO2023222135A1 (en) | A method of treating solid tumor | |
| TW202005983A (zh) | 抗-人類pd-l1之抗體及其用途 | |
| TWI889766B (zh) | 抗cd19抗體以及使用與製造其的方法 | |
| TW202400662A (zh) | 結合ｐｄ－ｌ１和ｃｌｄｎ１８．２的抗體及其用途 | |
| EP4681729A1 (en) | Pharmaceutical composition containing pd-1/pvrig/tigit binding protein and medical use thereof | |
| HK40112840A (zh) | 抗cd19抗体及其使用和制备方法 |